Physician profile
Chloe Aleena Wright
NPI 1245956770
$3,312.57
in general payments reported to CMS, 2019-2025
40 companies · $190 in 2025
The $190 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $122 · 2023: $1,297 · 2024: $1,704 · 2025: $190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,828 · Long Term Medical Supply Or Device Loan: $1,363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,827.79 |
| Long Term Medical Supply Or Device Loan | $1,363.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,583.04 | 2022-2025 | |
| Incyte Corporation | $168.92 | 2023-2024 | Jakafi, Monjuvi |
| E.R. Squibb & Sons, L.L.C. | $143.41 | 2023-2024 | Opdivo |
| Stemline Therapeutics INC. | $121.18 | 2023 | Orserdu |
| Eisai INC. | $88.74 | 2023-2024 | |
| Beigene USA, INC. | $86.23 | 2023 | Brukinsa |
| Astrazeneca Pharmaceuticals LP | $75.76 | 2022-2024 | Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $65.63 | 2023-2024 | |
| Pfizer INC. | $59.06 | 2023-2024 | |
| Tersera Therapeutics LLC | $57.53 | 2023 | Xermelo, Zoladex |
| Pharmacosmos Therapeutics INC. | $53.50 | 2023 | Monoferric |
| Genentech USA, INC. | $48.16 | 2023-2024 | Venclexta, Polivy, Lunsumio |
| Lilly USA, LLC | $47.83 | 2023-2024 | Verzenio, Jaypirca, Retevmo |
| Daiichi Sankyo INC. | $47.36 | 2022-2023 | Injectafer |
| Pharmaessentia USA Corporation | $47.05 | 2024-2025 | Besremi |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $43.75 | 2022-2023 | |
| Emd Serono, INC. | $43.60 | 2023-2024 | Tepmetko |
| Takeda Pharmaceuticals U.S.A., INC. | $42.51 | 2023-2024 | Iclusig, Ninlaro |
| Genmab U.S., INC. | $41.55 | 2023 | Epkinly |
| Janssen Biotech, INC. | $39.39 | 2023-2024 | Rybrevant, Erleada |
| Acrotech Biopharma INC. | $32.47 | 2023 | Beleodaq |
| Rigel Pharmaceuticals, INC. | $30.43 | 2023-2024 | Tavalisse, Rezlidhia |
| Karyopharm Therapeutics INC. | $24.93 | 2024 | Xpovio |
| Pharming Healthcare, INC. | $24.64 | 2024 | Ruconest |
| Pharmacyclics LLC, An Abbvie Company | $23.93 | 2022 | |
| Mirati Therapeutics, INC. | $22.27 | 2023 | Krazati |
| Seagen INC. | $22.01 | 2023 | Tukysa |
| Cumberland Pharmaceuticals, INC. | $20.75 | 2024 | Sancuso |
| Celgene Corporation | $20.55 | 2024 | Reblozyl |
| Abbvie INC. | $20.16 | 2023 | |
| Jazz Pharmaceuticals INC. | $19.79 | 2024 | |
| Alexion Pharmaceuticals, INC. | $18.62 | 2023 | Ultomiris |
| Adaptive Biotechnologies Corporation | $18.52 | 2024 | Clonoseq |
| Coherus Oncology, INC. | $16.92 | 2023 | |
| Deciphera Pharmaceuticals INC. | $16.70 | 2024 | Qinlock |
| Foundation Medicine, INC. | $16.07 | 2023 | |
| Sobi, INC | $15.67 | 2023 | |
| Merck Sharp & Dohme LLC | $15.56 | 2023 | Lynparza, Keytruda |
| Glaxosmithkline, LLC. | $14.33 | 2024 | Zejula |
| Amgen INC. | $14.05 | 2023 | Lumakras |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chloe Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.